



## JAGSONPAL PHARMACEUTICALS LIMITED

Regd. office : T-210 J. Shahpur Jat, New Delhi-110 049 (INDIA)

Fax : 0091-11-26498341, 26494708, Phone: 0091-11-26494519-24

E-mail: admin@jagsonpal.com

1. The Bombay Stock Exchange Limited, Mumbai Fax 022-22723121, 22722037, 22723719, 22723041  
2. The National Stock Exchange of India Ltd., Mumbai Fax 022- 26598237, 38

### Unaudited Financial Results for the Quarter ended 31.12.2009

(Rs. in lacs)

Particulars	Quarter	Quarter	3 Months	3 Months	12 Months
	ended 31.12.2009 Unaudited	ended 31.12.2008 Unaudited	ended 31.12.2009 Unaudited	ended 31.12.2008 Unaudited	ended 31.03.2009 Audited
1(a) Net sales/Income from Operations	3230.38	3855.90	10001.58	10384.60	13619.76
1(b) Other Operating Income					
Total	3230.38	3855.90	10001.58	10384.60	13619.76
2 Expenditure					
a. (Inc.)/Dec. in Stock in trade and work in progress	-84.58	365.00	-810.71	1188.52	787.24
b. Consumption of Raw Materials	1308.42	2039.19	4788.96	4251.99	6338.40
c. Purchase of traded goods	308.95	80.88	1352.91	630.77	764.68
d. Employees Cost	640.41	516.12	1774.69	1483.54	1969.07
e. Depreciation	50.05	29.00	149.88	97.49	124.88
f. Other Expenditure	649.37	401.30	1831.48	1685.35	2214.67
g. Total	2881.62	3431.29	9087.21	9337.66	12199.04
3 Profit from Operations before Other Income, Interest and Exceptional Items (1-2)	348.76	424.61	914.37	1046.94	1420.72
4 Other Income					27.06
5 Profit before Int. & Exceptional Items (3+4)	348.76	424.61	914.37	1046.94	1447.78
6 Interest	87.87	138.92	255.74	343.87	457.93
7 Profit After Interest but before Exceptional items (5-6)	260.89	285.69	658.63	703.07	989.85
8 Exceptional Items					
9 Profit(+)/Loss(-) from Ordinary Activities before tax (7 +8)	260.89	285.69	658.63	703.07	989.85
10 Tax expense	20.00	80.00	100.00	197.00	372.82
11 Net Profit(+)/Loss(-) from Ordinary Activities after tax (9+10)	240.89	205.69	558.63	506.07	617.23
12 Extraordinary Items (not of tax expense)					
13 Net Profit (+) Loss (-) for the period (11-12)	240.89	205.69	558.63	506.07	617.23
14 Paid up Eq. Sh. Cap. (Face value Rs. 5)	1309.90	1309.90	1309.90	1309.90	1309.90
15 Reserves excluding Revaluation reserves as per Balance sheet of pr. accounting yr.					5277.85
16 Earnings Per Share (EPS)					
a. Basic & diluted EPS before extraordinary items for the period	0.92	0.79	2.13	1.93	2.36
b. Basic & diluted EPS after extraordinary items for the period	0.92	0.79	2.13	1.93	2.36
17 Public shareholding					
- Number of shares	8962360	8962360	8962360	8962360	8962360
- Percentage of Shareholding	34.21%	34.21%	34.21%	34.21%	34.21%
18 Promoter and promoter group shareholding					
a. Pledged / Encumbered					
- Number of shares	-	-	-	-	-
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-
- Percentage of shares (as a % of the total share capital of the Company)	-	-	-	-	-
b. Non - encumbered					
- Number of shares	17235640	17235640	17235640	17235640	17235640
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%
- Percentage of shares (as a % of the total share capital of the Company)	65.79%	65.79%	65.79%	65.79%	65.79%

#### Notes

- The Financial Results for the Quarter ended 31.12.2009 have been reviewed by the Auditors as well as Audit Committee. The Board of Directors has taken on record the financial Results at its meeting held on 30-01-10.
- No complaints were pending at the beginning/end of the quarter ended 31.12.2009. However 38 requests for change of address/ dividend reinvestment/Annual Reports etc. were received & promptly responded to during the quarter.
- The Company is operating only in the Pharmaceuticals segment and hence compliance has been made under AS-17.
- The net effect of the deferred taxation for the Quarter as per AS-22 has been taken.



By Order of the Board  
For Jagsonpal Pharmaceuticals Limited

Rajpal Singh Kochhar  
Managing Director